Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
Background: Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer. However, patients with hormone receptor positive (especially human epidermal growth receptor 2 negative) breast cancer show low response rate to neoadjuvant chemotherapy. Whether...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2023-04-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/50/4/10.31083/j.ceog5004074 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer. However, patients with hormone receptor positive (especially human epidermal growth receptor 2 negative) breast cancer show low response rate to neoadjuvant chemotherapy. Whether neoadjuvant chemo-endocrine therapy (NCET) can improve the pathological complete response (pCR) rate of these patients remains controversial. Methods: A systematic literature search was conducted in the PubMed, Embase, and Cochrane databases. Pooled odds ratio (OR) with 95% confidence intervals (CI) was calculated. Results: Five randomized controlled trials were included (N = 566). NCET did not significantly improve pCR (OR 1.35, 95% CI 0.77–2.38, p = 0.30). Conclusions: NCET did not to improve the pCR rates in patients with hormone receptor positive breast cancer. |
|---|---|
| ISSN: | 0390-6663 |